Amgen Inc. (AMGN) drops 5.9% after Q1 earnings beat
Amgen Inc. (AMGN) drops after reporting first-quarter 2026 results, even though the company beat Wall Street on earnings and revenue. Investors appear focused on valuation, growth quality, and whether the quarter was strong enough to justify the stock’s premium.
Amgen Inc. (AMGN) drops about 5.9% after its Q1 2026 earnings report, even though the company beat Wall Street estimates on both earnings and revenue. The selloff reflects investor concern that the quarter was solid but not strong enough to justify the stock’s premium valuation, despite steady product growth and raised guidance. For investors, the move looks like an expectations reset rather than a sign of business deterioration.
Amgen Inc. (AMGN) drops sharply today, falling about 5.9% in regular trading after reporting first-quarter 2026 results. That move stands out because the company actually beat Wall Street on both earnings and revenue, which tells investors the selloff is less about the headline numbers and more about how the market is weighing growth quality, valuation, and the path ahead.
Key Takeaways
AMGN is down about 5.9% today, making it one of the weakest Nasdaq 100 names in Friday trading.
The clearest catalyst is Amgen’s Q1 2026 earnings report released on April 30, which drove the next-day reaction.
Q1 adjusted EPS came in at $5.15 versus a $4.73 consensus estimate, while revenue reached $8.62B versus $8.47B expected.
Despite the beat, the market appears to be focusing on whether mid-single-digit revenue growth and a roughly 24.3 P/E leave enough room for upside.
For investors, this looks more like a reset in expectations than a broken business, especially with 2026 revenue guidance of $37.1B to $38.5B and a 2.82% dividend yield.
Why Amgen Inc. Stock Drops After Q1 2026 Earnings
The most likely reason AMGN is sliding today is simple: the market is reacting to the earnings event itself. Amgen reported Q1 2026 results after the close on April 30, and the stock is being repriced in the next session.
On the surface, the quarter looked solid. Adjusted EPS was $5.15, ahead of the $4.73 consensus. Revenue was $8.62B, above the $8.47B estimate and up 5.8% from a year earlier. Earnings also rose from $4.90 in the prior-year quarter.
However, stocks do not trade on beats alone. They trade on the gap between investor hopes and the business trajectory that follows. In Amgen’s case, a 6% revenue gain and a beat against consensus were not enough to support the prior share price after the stock had already built in a fair amount of optimism.
That tension shows up in the broader setup. News sentiment around AMGN has been strongly positive, with a 7-day sentiment score of 0.8606, and Morgan Stanley even raised its price target to $332 from $326 on May 1. Yet the stock still sold off. When good news gets sold, the market is usually saying the bar was higher than the headline.
Amgen Financials Show a Solid Quarter but Not a Cheap Stock
Amgen remains a large, profitable drugmaker with a $175.88B market cap, trailing EPS of 14.23, and a P/E of about 24.3. That is not an extreme valuation for a high-quality biotech franchise, but it is also not a bargain multiple for a company growing revenue in the mid-single digits.
The company’s recent execution has been steady. Amgen has beaten EPS estimates in 6 of the last 7 reported quarters. This quarter continued that pattern, with an 8.87% EPS surprise. Revenue also topped expectations by 1.71%.
Still, the market often gets tougher on mature biopharma names when the stock price already reflects reliability. AMGN closed at $325.8932 before today’s move and trades well below its 52-week high of $391.29, but it is still far above its 52-week low of $253.4778. In other words, the shares were not priced for distress. They were priced for dependable growth.
That matters because dependable growth and accelerating growth are not the same thing. Investors often reward both, but they pay a higher multiple for the second one. Today’s decline looks like the market trimming that premium.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Product Growth at Amgen Supports the Business Even as the Stock Resets
The business itself still has real strengths. Amgen said 16 drugs delivered double-digit gains in the quarter. Product sales grew 4%, and key growth drivers generated $5.6B in Q1, or 70% of total product sales.
Several newer or expanding products posted strong numbers. Repatha sales reached $876M, up 34% year over year. Evenity brought in $562M, up 27%. Tezspire added $343M, up 20%. Those are healthy growth figures, and they support the case that Amgen is not simply living off older cash cows.
That said, Amgen still operates in a market that rarely gives mature pharma companies a free pass. Drug pricing pressure, biosimilar competition, and the need to keep replacing aging franchises are constant features of the business. The company’s own positioning reflects that balance. It has a broad portfolio across oncology, inflammation, rare disease, cardiovascular disease, and obesity-related conditions, but investors still want proof that newer products can carry more of the load over time.
This is where market psychology enters the room. A strong company can post a respectable quarter and still see its stock fall if traders decide the growth mix is sturdy rather than exciting. That distinction sounds small. On Wall Street, it is often the whole game.
For investors, today’s move looks more like an expectations reset than a sign of operational trouble. Amgen still guided for 2026 revenue of $37.1B to $38.5B, carries a consensus analyst target of $350.76, and offers a 2.82% dividend yield. Those facts support the idea that the business remains intact even as the stock absorbs a sharp one-day hit.
There is also a useful signal in the contrast between price action and analyst tone. Morgan Stanley lifted its target to $332 on May 1, while the broader analyst consensus remains Buy, with 22 buy ratings, 13 holds, and 3 sells. When a stock falls despite upbeat revisions, it usually means the market wanted a cleaner upside catalyst than it got.
That leaves AMGN in an interesting spot. At roughly 24.3 times earnings, the stock still carries a quality premium. But after a near 6% drop, some of the heat has come out of the trade. For long-term investors focused on durable earnings, product breadth, and income, that reset is more constructive than alarming.
Amgen’s decline today is best explained as a post-earnings selloff, even though the company beat on both EPS and revenue. The market is treating the quarter as solid but not strong enough to preserve a premium valuation, which is why AMGN drops even as the business fundamentals remain steady.
AMGN is down because investors are selling the stock after its Q1 2026 earnings report, even though results beat estimates. The market appears focused on valuation and whether growth is strong enough to support the current premium.
+Should I buy AMGN stock now?
The article suggests AMGN looks more like an expectations reset than a broken business, so long-term investors may find the pullback more attractive. Short-term traders may want to wait for the post-earnings volatility to settle.
+Did Amgen beat earnings expectations this quarter?
Yes. Amgen reported adjusted EPS of $5.15 versus the $4.73 consensus estimate. Revenue also came in above expectations at $8.62 billion.
+What does Amgen’s drop mean for investors?
It means the stock is being repriced after a solid quarter that did not fully meet market expectations for upside. The business remains intact, but investors are demanding stronger growth before paying a higher multiple.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on AMGN?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
